Continuous Subcutaneous Dopaminergic Stimulation: Exploring the impact of Foslevodopa/Foscarbidopa on Gait in Parkinson’s disease.
Objective: The primary objective of this study is to investigate the effect of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa (FL/FC) on gait in those with…Effect of Antihypertensive Agent Choice on Parkinson’s Disease Progression in Patients with Hypertension
Objective: To determine the effect of different classes of antihypertensive medications on Parkinson’s disease progression. Background: Cardiovascular risk factors such as hypertension can worsen Parkinson’s…L-DOPA Induced Iron Accumulation in the Ventral Midbrain: The Roles of Sex and Iron Repletion
Objective: This study aims to investigate the impact of L-3,4-dihydroxyphenylalanine (L-DOPA) on ventral midbrain (VMB) iron levels under iron deficiency (ID) and repletion (IR) conditions…The Effect of Foslevodopa/Foscarbidopa Treatment on Nonmotor Symptom Burden in Advanced Parkinson’s Disease
Objective: To investigate the impact of foslevodopa/foscarbidopa (LDp/CDp) on nonmotor symptoms (NMS) in adults with advanced Parkinson’s disease (aPD). Background: LDp/CDp, a 24-hour per day…Comparative Safety of Different Routes of Apomorphine Administration in Parkinson’s Disease: A Systematic Review and Meta-Analysis
Objective: To assess the safety profiles of inhaled, sublingual, and subcutaneous apomorphine in patients with Parkinson’s disease (PD). Background: Apomorphine is a direct-acting D1/D2 agonist…Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson’s Disease: Perspectives of Patients, Clinicians, and Caregivers
Objective: To evaluate the impact of Levodopa/Entacapone/Carbidopa Gel (LECIG) therapy on Parkinson’s disease (PD) patients, their caregivers, and clinicians over six months. Background: Advanced PD…Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis
Objective: To evaluate the type and timing of occurrence of treatment-emergent adverse events (AEs) in people with advanced Parkinson’s disease (PD) following up to one…Patient-derived α-synuclein seed amplification as a tool for evaluating small molecule aggregation inhibitors for Parkinson’s disease and Lewy Body Dementia therapeutics
Objective: To validate on-target engagement of disease-relevant ⍺-synuclein (a-syn) aggregates by WTX-607, WaveBreak’s small-molecule clinical candidate for Parkinson’s disease (PD) and Lewy body dementia (LBD),…Efficacy of Combined Transcranial Direct Current Stimulation (tDCS) and Gait Training on Gait in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Objective: To evaluate the effects of addition of tDCS to gait training on gait parameters and motor function in individuals with Parkinson’s disease Background: Gait…Smartphone-based digital assessments in the LUMA trial of BIIB122 for early-stage Parkinson’s disease
Objective: To evaluate the sensitivity of routine smartphone-based performance assessments in the free-living environment as part of a randomized clinical trial in Parkinson’s disease (PD).…
- « Previous Page
- 1
- …
- 321
- 322
- 323
- 324
- 325
- …
- 1942
- Next Page »